Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L; EXCEED Study Group. McInnes IB, et al. Among authors: masmitja jg. Lancet. 2020 May 9;395(10235):1496-1505. doi: 10.1016/S0140-6736(20)30564-X. Lancet. 2020. PMID: 32386593 Clinical Trial.
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
Landewé RB, Gensler LS, Poddubnyy D, Rahman P, Hojnik M, Li X, Liu Leage S, Adams D, Carlier H, Van den Bosch F; COAST-Y study group. Landewé RB, et al. Ann Rheum Dis. 2021 Aug;80(8):1022-1030. doi: 10.1136/annrheumdis-2020-219717. Epub 2021 May 6. Ann Rheum Dis. 2021. PMID: 33958326 Free PMC article. Clinical Trial.
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Järvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD; COAST-W Study Group. Deodhar A, et al. Arthritis Rheumatol. 2019 Apr;71(4):599-611. doi: 10.1002/art.40753. Epub 2019 Mar 8. Arthritis Rheumatol. 2019. PMID: 30343531 Free PMC article. Clinical Trial.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Outcome of an education and home-based exercise programme for patients with ankylosing spondylitis: a nationwide randomized study.
Rodríguez-Lozano C, Juanola X, Cruz-Martínez J, Peña-Arrébola A, Mulero J, Gratacós J, Collantes E; Spondyloarthropathies Study Group of the Spanish Society of Rheumatology. Rodríguez-Lozano C, et al. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):739-48. Epub 2013 Jul 24. Clin Exp Rheumatol. 2013. PMID: 23899791 Clinical Trial.
Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
Cruz Fernández-Espartero M, Pérez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gómez-Reino JJ, Carmona L; BIOBADASER Study Group. Cruz Fernández-Espartero M, et al. Semin Arthritis Rheum. 2011 Dec;41(3):524-33. doi: 10.1016/j.semarthrit.2011.05.003. Semin Arthritis Rheum. 2011. PMID: 22152489 Review.
12 results